ENDRA Life Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

ANN ARBOR, Mich.--(BUSINESS WIRE)---- $NDRA #MASLD--ENDRA Life Sciences Inc. (NASDAQ: NDRA) (“ENDRA” or the “Company”), a pioneer in thermoacoustic biomarker imaging for early detection and monitoring of steatotic liver disease (SLD), today reported financial results for the quarter and year ended December 31, 2025, and provided a business update. Business Update Initiated Evaluation of Strategic Alternatives On March 25, 2026, the Company announced that its Board of Directors has initiated a process to evaluat.